Last reviewed · How we verify
Preparation Varenicline and Extended Duration Varenicline
Preparation Varenicline and Extended Duration Varenicline is a Small molecule drug developed by University of Wisconsin, Madison. It is currently FDA-approved.
Varenicline, developed by the University of Wisconsin, Madison, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and extended duration formulation, which may offer a competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Preparation Varenicline and Extended Duration Varenicline |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cessation Screening Project (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Preparation Varenicline and Extended Duration Varenicline CI brief — competitive landscape report
- Preparation Varenicline and Extended Duration Varenicline updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI